Overview

TST002 Intervenous Injection in Postmenopausal Women and Men With Reduced Bone Mineral Density

Status:
Recruiting
Trial end date:
2023-06-28
Target enrollment:
Participant gender:
Summary
This is a placebo-controlled, single-ascending dose, multicenter Phase I clinical study to evaluate the safety, tolerability, PK and PD characteristics of a single intravenous infusion of TST002 in subjects with reduced bone mineral density.
Phase:
Phase 1
Details
Lead Sponsor:
HJB (Hangzhou) Co., Ltd.